Prolight Diagnostics announces today that the European Patent Office (EPO) has issued a Notice of Intention to Grant for the company’s third patent application related to its proprietary Psyros™single-molecule-counting technology. This is the third PsyrosTM patent to be granted by the EPO in 2025.
“We are delighted to receive confirmation that the EPO intends to grant another patent for our Psyros™ technology”, said Ulf Bladin, CEO of Prolight Diagnostics. “The pace at which our patents are being granted highlights the uniqueness of the technology and our strong freedom-to-operate.”
The Psyros™ technology uses photoactive reporter molecules to permanently bleach dark spots in a fluorescent layer, with each spot representing a single molecule binding event. This patent application (EP application number 23 716 913.1) protects a novel embodiment of the technology that uses light of two different wavelengths to generate the dark spots. Final formalities are now underway before the patent is officially granted under number EP 4 496 995.
Prolight currently holds six patent families related to the Psyros™ platform. The first three families are in the national or regional phases across territories worldwide. Families four and five are in the PCT phase and will enter the national/regional phases later this year. The sixth family is a priority application filed in the UK.
Earlier this year, patents from the first two families were granted in Europe and have since been validated in 17 European countries. Additionally, the first family patent was granted in Japan, further strengthening Prolight’s global intellectual property position.
